Letter t o the Editor
Pseudomonas aeruginosa is a leading cause of nosocomial infection. An increasing prevalence of multidrug-resistant P. aeruginosa has been reported worldwide. 1 The highest rates have been observed in Latin America, especially in Brazil. 2 Susceptibility patterns may have institutional variations due to multiple factors. Considering this, we performed an analysis of the susceptibility patterns of nosocomial isolates of P. aeruginosa to determine the magnitude of resistance to antipseudomonal agents at our institution. We also intended to identify a single susceptibility pattern more frequently associated with multidrug resistance. This kind of phenotypic marker could theoretically be useful to guide individual and institutional prescribing patterns for such strains to predict and prevent the emergence of the multidrug-resistant phenotype.
Clinical and surveillance isolates of P. aeruginosa were consecutively collected during September 2002 through July 2003 at Hospital Sao Lucas, a 600-bed, tertiary-care teaching hospital. Only one sample per patient was analyzed. If the patient had an isolate of multidrug-resistant P. aeruginosa following an isolate of non-multidrug-resistant P. aeruginosa, the latter was excluded. Strains isolated within 48 hours of patient admission were also excluded.
P. aeruginosa were identified by conventional microbiologic methods. 3 Antibiotic susceptibility tests were performed using the Kirby-Bauer disk-diffusion method according to the guidelines of the National Committee for Clinical Laboratory Standards. 4 Antibiotics tested included amikacin, aztreonam, ceftazidime, ciprofloxacin, imipenem, meropenem, piperacillin/tazobactam, and polymyxin B. Multidrug resistance was defined as resistance to three or more antipseudomonal agents of distinct classes. All statistical analyses were performed using SPSS software for Windows (version 10.0; SPSS, Inc., Chicago, IL). Odds ratios (ORs) and 95% confidence intervals (CI % ) were calculated. P values were calculated by chi-square.
A total of 189 P. aeruginosa isolates were identified during this period. Of those, 10 P. aeruginosa isolates were excluded because they were isolated from patients within 48 hours of hospital admission and 16 because they were isolated from patients with previous P. aeruginosa isolation (all of them with the same susceptibility pattern). Five isolates (one fully susceptible, two resistant to amikacin and ciprofloxacin, one resistant to amikacin and ceftazidime, and one resistant to ceftazidime and ciprofloxacin) were excluded because the same patients had previous isolates of multidrug-resistant P. aeruginosa.
A total of 158 isolates of P. aeruginosa were included in the study, corresponding to 7.1% of all bacterial isolates during this period. P. aeruginosa was isolated from patients hospitalized in medical and surgical wards. Sixty (38%) of the isolates were obtained from intensive care unit patients.
Ninety (57%) of the strains were resistant to three or more drugs. The most frequent susceptibility pattern defining multidrug resistance was resistance to all tested drugs except polymyxin B (16 strains; 17.8% of the multidrug-resistant P. aeruginosa), followed by resistance to amikacin, ceftazidime, ciprofloxacin, imipenem, and meropenem and susceptibility to aztreonam and piperacillin/tazobactam (14 strains; 15.6% of the multidrug-resistant P. aeruginosa) and resistance to amikacin, ceftazidime, ciprofloxacin, imipenem, meropenem, and piperacillin/tazobactam and susceptibility to aztreonam (13 strains; 14.4% of the multidrug-resistant P. aeruginosa).
P. aeruginosa isolates were more frequently recovered from respiratory secretions (22.2%), followed by urine (21.5%), nasal swabs (15.2%), blood (13.9%), surgical wounds (10.1%), central venous catheters (9.5%), and other secretions (7.6%). There were no statistically significant differences in the sites of isolation between multidrug-resistant P. aeruginosa and non-multidrug-resistant P. aeruginosa (P= .40).
All P. aeruginosa isolates were susceptible to polymyxin B. P. aeruginosa isolates showed resistance to ciprofloxacin (59.5% of resistance), imipenem (58.3%), amikacin (57.6%), meropenem (50.0%), ceftazidime (48.7%), piperacillin/ tazobactam (38.6%), and aztreonam (33.5%).
Determination of resistance to any antimicrobial drug tested was associated with resistance to three or more drugs ( The higher rates of resistance to antipseudomonal agents noted in our study seem to represent an increasing prevalence of resistance in P. aeruginosa as reported from other Latin American hospitals during the past few years.
2 This could be due to interinstitutional and intrainstitutional spread of multidrug-resistant/? aeruginosa clones (a hypothesis that is under investigation) or to local prescribing patterns, although there do not seem to be important differences in these patterns from other tertiarycare institutions (unpublished data).
We believe that the exclusion of five non-multidrug-resistant strains did not cause any important bias in our study because their inclusion would not likely cause major changes in the final results.
The current study failed to find a single antibiogram of multidrug resistance in our isolates because multiple patterns were involved. A prospective study would be able to follow the evolution of the susceptibility pattern of particular strains, using molecular typing, and would provide better understanding of how susceptibility profiles evolve to multidrug resistance. Although also associated with multidrug resistance, resistance to carbapenem drugs, especially meropenem, was less frequently associated with multidrug resistance at this institution.
Increasing resistance in P. aeruginosa, particularly that seen in Brazilian and Latin American centers, is of great concern because it has clinical and public health implications. Susceptibility patterns can have institutional variations and local surveillance is encouraged.
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